96. クローン病 Crohn disease Clinical trials / Disease details

臨床試験数 : 2,400 /  薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

  
10 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03266484
(ClinicalTrials.gov)		November 13, 201725/8/2017Effect of a Probiotic Mixture on the Gut Microbiome and Fatigue in Patients With Quiescent Inflammatory Bowel DiseaseEffect of Dietary Therapy With a Probiotic Mixture on the Gut Microbiome and Fatigue Symptoms in Patients With Quiescent Inflammatory Bowel Disease - A Clinical TrialInflammatory Bowel Diseases;Crohn Disease;Ulcerative ColitisDietary Supplement: Probiotic Mixture;Dietary Supplement: PlaceboMassachusetts General HospitalWinclove Bio Industries BVRecruiting18 Years75 YearsAll100N/AUnited States
2NCT01765439
(ClinicalTrials.gov)		February 20147/1/2013The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel DiseaseThe Effect of VSL#3 (Original De Simone Formulation) Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel DiseaseCrohn Disease;Ulcerative ColitisDietary Supplement: VSL#3 (Original De Simone formulation)Charles University, Czech RepublicIscare i.v.f., Czech Republic;CD Investments srl;University Of Perugia;University of Roma La SapienzaActive, not recruitingN/AN/AAll79N/ACzechia;Czech Republic
3NCT01765998
(ClinicalTrials.gov)		February 20136/1/2013The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease)The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of InflammationCrohn's DiseaseDrug: Probiotic;Drug: PlaceboThe Baruch Padeh Medical Center, PoriyaNULLNot yet recruiting18 Years60 YearsBoth60Phase 4Israel
4NCT01078935
(ClinicalTrials.gov)		December 20121/3/2010The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of InflammationThe Effect of Probiotics on Bowel DiseaseCrohn's Disease;Ulcerative ColitisDietary Supplement: probiotics;Dietary Supplement: placeboThe Baruch Padeh Medical Center, PoriyaMinistry of Health, IsraelNot yet recruiting18 Years80 YearsBoth100Phase 4NULL
5NCT01632462
(ClinicalTrials.gov)		September 201225/6/2012A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's DiseaseA Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's DiseaseCrohn's DiseaseDrug: VSL#3Federico II UniversityNULLRecruiting5 Years17 YearsBoth30Phase 4Italy
6NCT01548014
(ClinicalTrials.gov)		January 201017/2/2012The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's DiseaseReduction in Frequency of Infliximab Administration From q 8 Weeks to q 12 Weeks in Children With Crohn's Disease Receiving Probiotic VSL#3 Supplementation: A Pilot StudyCrohn's DiseaseDietary Supplement: VSL#3Samsung Medical CenterNULLRecruiting13 Years17 YearsBoth1Phase 3Korea, Republic of
7NCT00944736
(ClinicalTrials.gov)		July 200922/7/2009Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's DiseaseEffect of Probiotic VSL#3 on Intestinal Permeability of Pediatric Patients With Crohn's Disease in RemissionCrohn's DiseaseDietary Supplement: VSL#3;Dietary Supplement: PlaceboChildren's Mercy Hospital Kansas CityVSL PharmaceuticalsCompleted11 Years17 YearsBoth12Phase 3United States
8NCT00587041
(ClinicalTrials.gov)		February 200621/12/2007Use of Oral Probiotics to Reduce Urinary Oxalate ExcretionUse of Oral Probiotics to Reduce Urinary Oxalate ExcretionNephrolithiasis;Hyperoxaluria;Crohn's DiseaseDietary Supplement: Oxadrop;Dietary Supplement: Agri-King Synbiotic (AKSB);Other: PlaceboMayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institutes of Health (NIH);National Center for Complementary and Integrative Health (NCCIH);National Center for Research Resources (NCRR)Completed18 YearsN/AAll40Phase 1/Phase 2United States
9NCT00175292
(ClinicalTrials.gov)		December 200313/9/2005A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease.A Randomized and Placebo-Controlled Double-Blind Multicentre Study to Determine the Efficacy and Safety of VSL#3 Probiotic Food Supplement Mixture in Prevention of Endoscopic Recurrence in Crohn's Disease Patients With Ileocolonic Surgical Resection and Small Intestine to Colon Anastomosis.Crohn's Disease;Inflammatory Bowel DiseaseDrug: Probiotic - VSL#3University of AlbertaCanadian Institutes of Health Research (CIHR)Completed16 YearsN/ABoth120Phase 3Canada
10NCT00510978
(ClinicalTrials.gov)		January 20022/8/2007Probiotics in GastroIntestinal DisordersOne Year, Randomised, Double Blind, Placebo Controlled Trial of Probiotics, Bifidobacterium Infantis 35624 or Lactobacillus Salivarius UCC118, as Food Supplements for Maintenance of Remission in Crohn's Disease and Ulcerative ColitisUlcerative Colitis;Crohn's DiseaseBiological: Bifidobacterium infantis 35624;Biological: Lactobacillus salivarius UCC118;Biological: PlaceboUniversity College CorkEuropean CommissionActive, not recruitingN/A75 YearsBoth360Phase 2/Phase 3Ireland

先頭へ